Driving groundbreaking research. Improving lives.

Helping people with an MPN live a better quality of life as we work toward answers to prevention, progression and a cure for polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) – blood cancers collectively known as myeloproliferative neoplasms.

MPNRF By the Numbers

$ 0 M

What is Primary Myelofibrosis (MF)?

Primary Myelofibrosis (MF)

PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF

What is Essential Thrombocythemia (ET)?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is Polycythemia Vera (PV)

Polycythemia Vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

Recent News

  • Richard T. Silver, MD

    MPN NEWS | September 7, 2022

    Before he helped define criteria for the diagnosis of polycythemia vera (PV) and introduced interferon to treat it; before he chaired the guidelines committee for the treatment of chronic myeloid leukemia (CML) for the American Society of Hematology; and long before his name branded an internationally recognized clinic that specializes in myeloproliferative neoplasms (MPNs); Richard… Read More »Richard T. Silver, MD


    30 FACTS about MPNs

    MPN NEWS | August 22, 2022

    Our investments in global, cutting edge, multi-center MPN research have directly advanced knowledge about the causes of these rare, chronic blood cancers, leading to the development of more and better treatments and improved quality of life for people living with an MPN. Clinical trials are an integral part of this process. 30 FACTS ABOUT MPN… Read More »30 FACTS about MPNs


    Advances of Note From EHA2022 

    MPN NEWS | July 29, 2022

    The European Hematology Association’s EHA2022 Congress in Vienna brought together global research leaders, practitioners, and other participants in June to share the latest advances in hematology. Among those on MPNs were the following:   “ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFa axis mediated inflammation and fibrocyte generation in myeloproliferative neoplasms”   This study illustrated the crucial role… Read More »Advances of Note From EHA2022 

  • Ready to do more?

    Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

    Stay Connected

    With your generous gift, you can change a MPN patient’s prognosis.

    By supporting MPN Research Foundation, you’re also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.


    Want to learn more about MPNs? Be the first to know about what’s going on in the PV, ET, and MF community.
    Get our monthly update,
    Under the Microscope